Clinical trial
Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria
NCT00004831 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00004831 |
|---|---|
| Title | Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Collaborators | St. Luke's-Roosevelt Hospital Center |
| Status | Completed |
| Study type | Interventional |
| Conditions | Erythropoietic Protoporphyria |
| Intervention type | Drug |
| Interventions | cysteine hydrochloride |
| Enrollment | 20 |
| Start date | Oct 1, 1996 |
| Completion | Jul 1, 1998 |
| First posted | Feb 25, 2000 |
| Last update posted | Mar 25, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: